fbpx

molecules of the month

PF-06843195

oral PI3K_-selective kinase inhibitor prodrug

preclinical candidate for breast cancer

from mining of prior PI3K inh., SBDD, and opt.

J. Med. Chem., Dec. 24, 2020

Pfizer, San Diego, CA

Structure of oral PI3K_-selective kinase inhibitor prodrug PF-06843195
1 min read

Pfizer oral PI3ka-selective kinase inhibitor prodrug


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: